Medical Guidance: Chief Physician Ma Jinping, Gastrointestinal Surgery, Zhongshan No. 1 Hospital
Medical Expertise: Proficient in laparoscopic radical surgery for common gastrointestinal and pancreatic clinical conditions, including gastric cancer, gastrointestinal stromal tumor resection, and laparoscopic radical surgery for colon and rectal cancer at various sites. Experienced in organ-preserving radical surgery for intestinal cancer; proficient in surgical treatment of benign and malignant pancreatic diseases; skilled in weight loss metabolic surgery; adept in procedures such as pancreaticoduodenectomy and radical treatment of esophageal cancer, as well as surgical management of malignant tumors of the duodenum; familiar with various surgical treatments for inguinal and incisional hernias; possesses rich clinical experience with common anorectal conditions, such as different types of hemorrhoids.
(Image source: Internet)
In recent years, many people who feel “overweight” may have tried a new “weight loss drug” — Semaglutide. With weekly injections, weight drops noticeably, and its visible weight loss effects are becoming increasingly popular. It is said that even Tesla’s boss, Elon Musk, has praised it.
What exactly is the “weight loss drug” Semaglutide?
What kind of “miracle drug” is Semaglutide for weight loss?
Semaglutide injection, in fact, is an incretin, a new long-acting glucagon-like peptide-1 (GLP-1) analog. It is based on the human GLP-1 molecule, modified to resist degradation by dipeptidyl peptidase-4 (DPP-4), tightly binds with albumin, significantly extending its half-life in the body while retaining up to 94% homologous amino acid sequence of GLP-1, providing good safety.
In simple terms, Semaglutide is a “mimic” of the glucagon-like peptide-1 (GLP-1), which is a substance synthesized by the intestine that promotes insulin release and lowers blood sugar when glucose levels rise.
(Image source: Internet)
As a human GLP-1 analog, Semaglutide stimulates insulin secretion in a glucose-dependent manner and reduces glucagon secretion. This means that GLP-1 is only activated to exert its effects when glucose levels in the body rise, stimulating insulin secretion and inhibiting glucagon secretion. If blood sugar is normal, injecting more GLP-1 will not produce effects. This mechanism of action helps reduce the occurrence of hypoglycemia while lowering blood sugar.
Semaglutide was originally used clinically primarily for the treatment of diabetes, but current studies indicate that it also has weight loss effects.
Semaglutide has weight loss effects
(Image source: Internet)
